Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
221-240 of 1,743 trials

Advanced Non-Small Cell Lung Cancer: Cemiplimab and BNT116 Combination

We are studying how a new cancer vaccine combined with cemiplimab works for adults with advanced non-small cell lung cancer. This trial will help us understand its effectiveness and safety compared to cemiplimab alone.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Atrial Fibrillation: Abelacimab Treatment Study

We are studying whether abelacimab can help high-risk patients with atrial fibrillation who cannot take oral blood thinners. The goal is to see if it reduces the risk of strokes and other serious complications compared to a placebo.

Atrial Fibrillation>2 yearsConfirmation phase (III)>20 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Colorectal Cancer: Flu Vaccine and Pembrolizumab Study

We are exploring whether a flu vaccine combined with pembrolizumab can help shrink tumors in patients with early pMMR colorectal cancer. The study will also assess safety and immune responses.

Colorectal Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Pleural Mesothelioma: Volrustomig with Carboplatin and Pemetrexed

We are studying a new treatment combination for patients with unresectable pleural mesothelioma. The goal is to see if it works better than current standard care options.

Unresectable Pleural Mesothelioma>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Endometrial Cancer: RAINBO Treatment Study

We are exploring a new treatment approach for patients with endometrial cancer based on their molecular features. The goal is to see if this can improve survival rates and reduce the chance of cancer returning.

Mismatch Repair Deficient High-Risk Endometrial Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsOncology

Mitapivat for Erythrocyte Membranopathies

We are studying the safety and effects of mitapivat in adults with erythrocyte membranopathies. This includes looking at hemoglobin levels and how it may help with symptoms.

Erythrocyte Membranopathies>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematology

Postpartum Anemia: IV vs. Oral Iron Treatment

We are studying whether intravenous iron is more effective than oral iron in reducing postpartum depression and improving anemia in women after cesarean delivery. This trial will help us understand the best treatment options for new mothers facing these challenges.

Postpartum Depression with Iron Deficiency Anemia>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsPsychiatry

Melanoma Treatment: ABP 206 vs. OPDIVO

We are evaluating a new treatment, ABP 206, for patients with advanced melanoma who have not been treated before. The study aims to see how well it works and how safe it is compared to OPDIVO.

Metastatic Melanoma>2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Bronchiectasis: Long-Term Study of BI 1291583

We are testing the long-term safety of BI 1291583 in people with bronchiectasis who have taken part in earlier studies. The study will also look at whether this treatment helps reduce lung flare-ups.

Bronchiectasis>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Malignant Pleural Effusion: Pressurized Aerosol Chemotherapy

We are testing a new method of delivering chemotherapy directly into the chest for patients with malignant pleural effusion. This study aims to evaluate how well this treatment works and its safety.

Malignant Pleural Effusion>2 yearsSafety phase (I)OncologyPulmonology

Daridorexant for Insomnia in Alzheimer's Patients

We are studying whether daridorexant can improve sleep quality in individuals with mild cognitive impairment and mild to moderate Alzheimer's disease. This trial aims to evaluate its effects on sleep duration, daytime functioning, and overall health.

Insomnia Disorder>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementNeurologyPsychiatry

Tislelizumab for Cancer Patients with Residual Disease

We are studying whether tislelizumab can help cancer patients who still have detectable disease after standard treatment. The goal is to see if it improves their chances of staying cancer-free compared to a placebo.

Pancreatic CancerSoft Tissue SarcomaNon-Small Cell Lung Cancer>2 yearsConfirmation phase (III)16-20 visitsStandard MedicinesPartially RemoteGastroenterologyOncologyPulmonology

Ewing Sarcoma: Regorafenib with Chemotherapy

We are studying a new combination of regorafenib and standard chemotherapy for patients with newly diagnosed multimetastatic Ewing sarcoma. The goal is to find the best dose and evaluate its safety and effectiveness.

Metastatic Ewing Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncologyOrthopedics and Traumatology

Oligometastatic Non-Small Cell Lung Cancer: Immunotherapy with Local Treatments

We are studying whether adding a local treatment to standard immunotherapy helps improve survival for patients with oligometastatic non-small cell lung cancer. This trial will also look at quality of life and side effects.

Synchronous Oligometastatic Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesOncologyPulmonology

Chronic Myeloid Leukemia: ELVN-001 Treatment

We are investigating a new drug, ELVN-001, for patients with chronic myeloid leukemia. The goal is to see if it is safe and effective in treating this type of cancer.

Chronic Myeloid Leukemia>2 yearsSafety phase (I)HematologyOncology

Lung Cancer Treatment: MK-2870 with Pembrolizumab

We are comparing a new combination treatment for metastatic non-small cell lung cancer to standard therapy. This study aims to see if the combination improves survival and quality of life for patients with high PD-L1 levels.

Metastatic Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesOncology

Light Chain Amyloidosis: Etentamig Treatment Study

We are evaluating the safety and effectiveness of Etentamig for individuals with Light Chain Amyloidosis. This study aims to understand how well this treatment works for managing the disease.

Light Chain Amyloidosis>2 yearsSafety phase (I)HematologyOncology

E. coli Urinary Tract Infection: Pivmecillinam Treatment

We are studying whether an oral medication called pivmecillinam is as effective as standard treatments for E. coli urinary tract infections. This trial will also assess safety and other health effects.

Febrile Urinary Tract Infection>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInfectious DiseasesUrology

Follicular Lymphoma: Tisagenlecleucel vs. Standard Care

We are studying a new treatment called tisagenlecleucel for adults with relapsed or refractory follicular lymphoma. The goal is to see if it helps patients live longer and respond better than current standard treatments.

Follicular Lymphoma>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Panguian Clinical Trial

We are exploring a new treatment in this clinical trial. Participants will help us understand its effects and potential benefits.

Rheumatoid Arthritis>2 yearsConfirmation phase (III)Monitoring phase (IV)Orthopedics and Traumatology